Impact Biomedical (IBO) Interest Coverage Ratio (2022 - 2026)
Impact Biomedical's (IBO) quarterly Interest Coverage Ratio came in at 0.21 in Q1 2026, up 73.67% YoY from 0.12 in Q1 2025, and up 75.28% on a QoQ basis from 0.84 in Q3 2025.
Impact Biomedical (IBO) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Interest Coverage Ratio data on file, last reported at 0.21 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 73.67% year-over-year to 0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.49 (up 97.84% YoY) and the FY2024 annual result came in at 25.83, down 8465.94% from the prior year.
- Interest Coverage Ratio climbed to 0.21 in Q1 2026, from 0.84 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.21 in Q1 2026 to a low of 97.15 in Q4 2024.
- A 5-year average of 9.77 and a median of 0.97 in 2023 frame the typical range for Interest Coverage Ratio.
- The widest YoY moves for Interest Coverage Ratio: up 91.29% in 2024, down 966.2% in 2024.
- Tracing IBO's Interest Coverage Ratio over 5 years: stood at 10.42 in 2022, then climbed by 12.59% to 9.11 in 2023, then plunged by 966.2% to 97.15 in 2024, then soared by 99.14% to 0.84 in 2025, then surged by 75.28% to 0.21 in 2026.
- The last three Interest Coverage Ratio figures came in at 0.21 (Q1 2026), 0.84 (Q3 2025), and 0.9 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Impact Biomedical | 49.45 Mn | 49.44 Mn | 2,000.00 | -10.48 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.06 |
| Mar 31, 2026 | -0.21 |
| Sep 30, 2025 | -0.84 |
| Jun 30, 2025 | -0.90 |
| Mar 31, 2025 | -0.79 |
| Dec 31, 2024 | -97.15 |
| Sep 30, 2024 | -1.01 |
| Jun 30, 2024 | -0.56 |
| Mar 31, 2024 | -0.69 |
| Dec 31, 2023 | -9.11 |
| Sep 30, 2023 | -0.97 |
| Jun 30, 2023 | -0.91 |
| Mar 31, 2023 | -7.95 |
| Dec 31, 2022 | -10.42 |
| Sep 30, 2022 | -9.66 |
| Jun 30, 2022 | -5.40 |